02.14.25 -- They Said What? Unexpected Insights Into CDMO Selection

The authors conclude their four-part article series on computer systems validation (CSV) pitfalls using real case studies to illustrate points related to inattention to details.

Lonza principle scientist Deanna Mudie Ph.D. covers the design of dissolution media to support biopredictive dissolution testing and how the properties of a drug and formulation affect performance.

Explore the importance of particle size characterization and the advanced analytical techniques employed to assess micronized particles effectively.

Ensure drug stability and safety with forced degradation and photo-stability testing, following ICH and FDA guidelines to identify degradation pathways and light exposure risks.

As peptide therapeutics continue to establish themselves as a leading technology for treating chronic indications, drug sponsors must identify reliable building block suppliers to secure high-quality materials.

When facing a malfunction, having an effective disaster recovery plan can make the difference between a swift fix, and losing your samples and time.

Highly potent materials bring additional challenges to manufacturing processes. Examine considerations for optimizing HPAPI production methods to reduce risk and deliver therapies to patients with speed.

Consider contract blister packaging services from a partner that can produce blister packaging in several different forms, including regular thermo-form, cold-formed, and heat-sealed blister cards.

For poorly soluble drugs, overcoming absorption hurdles can hinder development. Consider a solution that empowers researchers to overcome solubility limitations and accelerate drug development.

Early identification of potential absorption risks is critical for rapid and efficient drug development. Lonza's PBPK modeling services are designed to de-risk your drug development program.